Focus on Tricuspid, Mitral, and Aortic Valve Interventions
Combined Mitral and Tricuspid Versus Isolated Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Symptomatic Valve Regurgitation at High Surgical Risk

https://doi.org/10.1016/j.jcin.2018.04.010Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

The present study aimed to test the clinical benefit of combined transcatheter mitral plus tricuspid valve edge-to-edge repair (TMTVR) as compared with transcatheter mitral valve edge-to-edge repair (TMVR) alone in patients with both significant mitral (MR) and tricuspid regurgitation (TR) at high surgical risk.

Background

A growing number of patients with severe MR at increased surgical risk are treated by transcatheter techniques. Evidence suggests that residual TR remains a predictor of adverse outcome in these patients.

Methods

Sixty-one patients (mean age 79.5 ± 8.4 years, EuroSCORE II 8.6 ± 5.9%) underwent TMTVR (n = 27) or TMVR (n = 34). Echocardiographic and cardiac magnetic resonance imaging was performed before and after the procedure.

Results

Reduction of MR was similar in patients undergoing TMTVR and TMVR. Effective regurgitant orifice area of TR was reduced from 0.51 to 0.29 cm2 in patients with TMTVR (p < 0.01), but remained unchanged after TMVR. On cardiac magnetic resonance imaging, only patients in the TMTVR group exhibited improved effective right and left ventricular stroke volume, and increased cardiac index (2.1 vs. 2.5 l/min/m2; p < 0.01). TMTVR led to superior improvement in New York Heart Association functional class, NT-proBNP levels, and 6-min walking distance as compared with TMVR. After up to 18 months of follow-up, patients with TMTVR experienced fewer hospitalizations for heart failure when compared with patients with TMVR (p = 0.02), whereas rates of death were comparable between both groups of patients.

Conclusions

TMTVR appears superior to TMVR in terms of cardiac output and functional improvement early after the intervention, and improves clinical outcome up to 18 months of follow-up.

Key Words

edge-to-edge repair
mitral regurgitation
mitral valve
transcatheter therapy
tricuspid regurgitation
tricuspid valve

Abbreviations and Acronyms

2D/3D
2-dimensional/3-dimensional
6MWD
6-min walk test distance
CMR
cardiac magnetic resonance
EROA
effective regurgitant orifice area
EDV
end-diastolic volume
ESV
end-systolic volume
ICD
implantable cardioverter-defibrillator
IQR
interquartile range
LV
left ventricular
LVEF
left ventricular ejection fraction
MR
mitral regurgitation
NT-proBNP
N-terminal pro–B-type natriuretic peptide
NYHA
New York Heart Association
PISA
proximal isovelocity surface area
RV
right ventricular
SV
stroke volume
TAPSE
tricuspid annular plane systolic excursion
TMTVR
transcatheter mitral plus tricuspid valve edge-to-edge repair
TMVR
transcatheter mitral valve edge-to-edge repair
TR
tricuspid regurgitation
VC
vena contracta

Cited by (0)

Dr. Borger has been on Speakers Bureaus and/or served as a consultant for Edwards Lifesciences, Medtronic, St. Jude Medical, and CryoLife. Dr. Lurz is a consultant to and has received speaker honoraria from Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The first 2 authors contributed equally to this work.